Loading...
By Kristin J. Kelley
Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM
Liraglutide injection (marketed as Victoza) can now be used to treat type 2 diabetes in children aged 10 years and older. It's the first non-insulin drug approved for pediatric patients in almost two decades, since metformin got the OK in 2000.
Liraglutide has been used for adults since 2010. Pediatric approval was based on results from a phase III study in which children on liraglutide achieved lower mean glycated hemoglobin and fasting glucose levels than those given placebo (see Background link for more details).
The FDA notes that the drug is not indicated to reduce cardiovascular events in children as it is in adults, nor is it indicated for patients of any age with type 1 diabetes or diabetic ketoacidosis. Additionally, the label includes a boxed warning about an increased risk for thyroid C-cell tumors, as well as warnings for acute gallbladder disease, hypoglycemia, pancreatitis, and renal impairment. The most common side effects include constipation, diarrhea, nausea, and vomiting.
Comment
LINK(S):
FDA news release (Free)
Background: NEJM Journal Watch Pediatrics and Adolescent Medicine coverage of liraglutide in youth (Your NEJM Journal Watch subscription required)